Soligenix Stock Soars 260% On Positive Results For Behçet's Disease Treatment

(RTTNews) - Soligenix, Inc. (SNGX) shares surged 260.00 percent to $4.50 after announcing that its Phase 2a proof-of-concept study for SGX945 in Behçet's Disease achieved its primary goal of demonstrating biological efficacy.

The stock opened at $1.9010 and traded between $1.6600 and $3.3599, with volume spiking to 174 million shares, vastly exceeding the average of 919,691 on the Nasdaq. Shares had previously closed at $1.2500. The stock now trades near the upper end of its 52-week range of $1.0900 to $5.4000.

The treatment showed comparable results to apremilast in reducing oral ulcers, despite SGX945 being discontinued at week 4, while apremilast continued through week 8—suggesting sustained therapeutic benefit even post-treatment.